CSL Limited (OTCMKTS:CSLLY - Get Free Report) was up 2.4% on Wednesday . The stock traded as high as $84.02 and last traded at $83.81. Approximately 43,717 shares traded hands during mid-day trading, a decline of 51% from the average daily volume of 88,658 shares. The stock had previously closed at $81.87.
Analysts Set New Price Targets
Separately, The Goldman Sachs Group upgraded CSL to a "strong-buy" rating in a report on Thursday, January 16th.
View Our Latest Research Report on CSLLY
CSL Trading Up 1.0 %
The firm has a fifty day moving average price of $84.77 and a two-hundred day moving average price of $91.97. The company has a quick ratio of 0.97, a current ratio of 2.18 and a debt-to-equity ratio of 0.58.
About CSL
(
Get Free Report)
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants.
See Also
Before you consider CSL, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CSL wasn't on the list.
While CSL currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
